Table 2.
Comparison of baseline variables in patients receiving TDF and ETV
| Variable | TDF | ETV | P | ||
|---|---|---|---|---|---|
| Patients, n (%) | 107 | (45.92) | 126 | (54.08) | |
| Male sex, n (%) | 82 | (76.63) | 107 | (84.92) | 0.08 |
| Age, M (range) | 52 | (25–69) | 55 | (26–73) | 0.31 |
| CTP class A/B/C, n (%) | 0.11 | ||||
| A | 105 | (98.13) | 122 | (96.82) | |
| B | 2 | (1.87) | 4 | (3.18) | |
| C | 0 | 0 | |||
| HBV DNA, log copies/ml | 3.7 | (3.0–4.7) | 4.1 | (3.0–5.1) | 0.07 |
| HBeAg postive, n (%) | 76 | (71.03) | 88 | (69.84) | 0.14 |
| Cirrhosis, n (%) | 59 | (55.14) | 37 | (29.36) | 0.03 |
| AFP, ng/mL, M (range) | 97.5 | (7.8–1210) | 109 | (10.3–1210) | 0.33 |
| Tumor maximum size, cm, M (range) | 3.8 | (2.8–9.7) | 4.4 | (2.6–8.5) | |
| TBIL, mmol/L, M (range) | 4.78 | (2.6–64.7) | 7.41 | (3.90–54.30) | 0.16 |
| ALT, IU/L, M (range) | 21 | (11–41) | 27 | (19–57) | 0.11 |
| AST, IU/L, M (range) | 28 | (19–56) | 21 | (20–78) | 0.41 |
| ALP, IU/L, M (range) | 49 | (45–111) | 58 | (51–187) | 0.09 |
| ALB, g/L, M (range) | 3.5 | (2.3–5.7) | 4.1 | (2.5–5.1) | 0.64 |
| PLT, 10^9/L, M (range) | 134.24 | (79–241) | 183 | (99–210) | 0.21 |
| PT, s, M (range) | 11.9 | (11.3–12.6) | 12.5 | (11.7–13.6) | 0.08 |
| INR, M (range) | 1.01 | (0.77–1.24) | 0.97 | (0.81–1.21) | 0.51 |
AFP = α-fetoprotein, ALB = albumin, ALP = alkaline phosphatase,ALT = alanine aminotransferase, AST = aspartate aminotransferase, CTP=Child–Trucott–Pugh score, HBV = hepatitis B virus, INR = international normalized ratio, PLT = platelet, PT = prothrombin time, TBIL = total bilirubin